Trial Profile
Clinical efficacy of intravenous calcium-sensing receptor agonist (etelcalcetide hydrochloride) for secondary hyperparathyroidism
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2020
Price :
$35
*
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- 06 Jul 2020 Status changed from active, no longer recruiting to completed.
- 21 May 2020 Planned End Date changed from 31 Mar 2021 to 31 May 2021.
- 30 Oct 2019 Planned End Date changed from 31 Mar 2019 to 31 Mar 2021.